616 related articles for article (PubMed ID: 15768830)
1. The Caveolin genes: from cell biology to medicine.
Williams TM; Lisanti MP
Ann Med; 2004; 36(8):584-95. PubMed ID: 15768830
[TBL] [Abstract][Full Text] [Related]
2. Caveolae, caveolin, and cavins: potential targets for the treatment of cardiac disease.
Das M; Das DK
Ann Med; 2012 Sep; 44(6):530-41. PubMed ID: 21651441
[TBL] [Abstract][Full Text] [Related]
3. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease.
Hnasko R; Lisanti MP
Mol Interv; 2003 Dec; 3(8):445-64. PubMed ID: 14993453
[TBL] [Abstract][Full Text] [Related]
4. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
Smythe GM; Eby JC; Disatnik MH; Rando TA
J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
[TBL] [Abstract][Full Text] [Related]
5. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype.
Park DS; Woodman SE; Schubert W; Cohen AW; Frank PG; Chandra M; Shirani J; Razani B; Tang B; Jelicks LA; Factor SM; Weiss LM; Tanowitz HB; Lisanti MP
Am J Pathol; 2002 Jun; 160(6):2207-17. PubMed ID: 12057923
[TBL] [Abstract][Full Text] [Related]
6. Getting rid of caveolins: phenotypes of caveolin-deficient animals.
Le Lay S; Kurzchalia TV
Biochim Biophys Acta; 2005 Dec; 1746(3):322-33. PubMed ID: 16019085
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade.
Woodman SE; Park DS; Cohen AW; Cheung MW; Chandra M; Shirani J; Tang B; Jelicks LA; Kitsis RN; Christ GJ; Factor SM; Tanowitz HB; Lisanti MP
J Biol Chem; 2002 Oct; 277(41):38988-97. PubMed ID: 12138167
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis.
Sonveaux P; Martinive P; DeWever J; Batova Z; Daneau G; Pelat M; Ghisdal P; Grégoire V; Dessy C; Balligand JL; Feron O
Circ Res; 2004 Jul; 95(2):154-61. PubMed ID: 15205364
[TBL] [Abstract][Full Text] [Related]
9. The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction.
Schlegel A; Lisanti MP
Cytokine Growth Factor Rev; 2001 Mar; 12(1):41-51. PubMed ID: 11312118
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts.
Cohen AW; Park DS; Woodman SE; Williams TM; Chandra M; Shirani J; Pereira de Souza A; Kitsis RN; Russell RG; Weiss LM; Tang B; Jelicks LA; Factor SM; Shtutin V; Tanowitz HB; Lisanti MP
Am J Physiol Cell Physiol; 2003 Feb; 284(2):C457-74. PubMed ID: 12388077
[TBL] [Abstract][Full Text] [Related]
11. Caveolae and caveolin-3 in muscular dystrophy.
Galbiati F; Razani B; Lisanti MP
Trends Mol Med; 2001 Oct; 7(10):435-41. PubMed ID: 11597517
[TBL] [Abstract][Full Text] [Related]
12. Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress.
Volonté D; Galbiati F; Pestell RG; Lisanti MP
J Biol Chem; 2001 Mar; 276(11):8094-103. PubMed ID: 11094059
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia.
Frank PG; Lisanti MP
Curr Opin Lipidol; 2004 Oct; 15(5):523-9. PubMed ID: 15361787
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 deficiency stimulates neointima formation during vascular injury.
Hassan GS; Jasmin JF; Schubert W; Frank PG; Lisanti MP
Biochemistry; 2004 Jul; 43(26):8312-21. PubMed ID: 15222744
[TBL] [Abstract][Full Text] [Related]
15. Urogenital alterations in aged male caveolin-1 knockout mice.
Woodman SE; Cheung MW; Tarr M; North AC; Schubert W; Lagaud G; Marks CB; Russell RG; Hassan GS; Factor SM; Christ GJ; Lisanti MP
J Urol; 2004 Feb; 171(2 Pt 1):950-7. PubMed ID: 14713860
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.
Razani B; Engelman JA; Wang XB; Schubert W; Zhang XL; Marks CB; Macaluso F; Russell RG; Li M; Pestell RG; Di Vizio D; Hou H; Kneitz B; Lagaud G; Christ GJ; Edelmann W; Lisanti MP
J Biol Chem; 2001 Oct; 276(41):38121-38. PubMed ID: 11457855
[TBL] [Abstract][Full Text] [Related]
17. Caveolin proteins: a molecular insight into disease.
Yin H; Liu T; Zhang Y; Yang B
Front Med; 2016 Dec; 10(4):397-404. PubMed ID: 27896622
[TBL] [Abstract][Full Text] [Related]
18. Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells.
Sotgia F; Razani B; Bonuccelli G; Schubert W; Battista M; Lee H; Capozza F; Schubert AL; Minetti C; Buckley JT; Lisanti MP
Mol Cell Biol; 2002 Jun; 22(11):3905-26. PubMed ID: 11997523
[TBL] [Abstract][Full Text] [Related]
19. Role of caveolae and caveolins in health and disease.
Cohen AW; Hnasko R; Schubert W; Lisanti MP
Physiol Rev; 2004 Oct; 84(4):1341-79. PubMed ID: 15383654
[TBL] [Abstract][Full Text] [Related]
20. Genetic ablation of caveolin-1 confers protection against atherosclerosis.
Frank PG; Lee H; Park DS; Tandon NN; Scherer PE; Lisanti MP
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):98-105. PubMed ID: 14563650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
